A recent study published in Vaccine argues that adverse events (AEs) are an important factor in vaccine cost-effectiveness analyses. The study surveyed 67 studies and received a 40% response rate from corresponding authors. Their findings show that analyses often exclude AEs for three main reasons: they are perceived as too rare and thus irrelevant (65%), studies follow established methodologies that omit AEs (35%), or there is simply insufficient data to include them (33%).
Excluding AEs in cost-effectiveness analysis could affect the price/benefit profile of a vaccine and, therefore, influence price negotiations or resource allocation. The authors argue for the development of better conceptual frameworks and the systematic collection of AE data to support comprehensive economic evaluations. Enhancing the rigor of vaccine economic assessments will yield more accurate and transparent guidance for immunization policymakers—safeguarding both public health and investment efficiency.
Thumbnail image credit: Gavi
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.